CIK 0001907108
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Lexeo Therapeutics, Inc.
Sign in to watch- Ticker
- LXEO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 854012572
- Phone
- +1 212-547-9879
- Business address
- 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK, NY, 10010
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Executive Officer sold 2,500 shares at $7.82 ($19,557)
- 3 Insider Initial Statement of Ownership
- 4 Planned sale Chief Executive Officer sold 5,000 shares at $8.10 ($40,496)
- 4 Planned sale Chief Executive Officer sold 5,000 shares at $10.65 ($53,274)
- 4 Planned sale Chief Executive Officer sold 5,000 shares at $11.53 ($57,635)
- 4 Planned sale Chief Executive Officer sold 55,000 shares at an average $16.79 ($923,388)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Technical Officer acquired 31,250 shares (grant or award)
- 4 Planned sale Chief Executive Officer sold 5,000 shares at an average $17.65 ($88,264)
- 3 Insider Initial Statement of Ownership
- 4 Planned sale Chief Executive Officer sold 5,000 shares at $13.22 ($66,093)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
Page 5 of 7 · 121 filings